/PRNewswire/ DelveInsight s Multiple Myeloma Market Insights report includes a comprehensive understanding of current treatment practices, multiple myeloma.
Pembrolizumab led to sustained improvements in recurrence-free survival and distant metastasis-free vs placebo as adjuvant therapy in patients with resected stage IIB or IIC melanoma
Treatment with the oral, small-molecule Wee1 kinase inhibitor adavosertib was clinically active but not well tolerated in patients with recurrent or persistent uterine serous carcinoma who previously received platinum-based chemotherapy.
Roche-backed startup Arch Oncology drops anti-CD47 antibody and lays off entire staff; Researchers posit that aging is a reversible process based on experiments in mice.